Federal Register Government Regulation Clinical Trials Drug Regulation Opioid Use Disorder Psychedelic Drugs

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information

By Health, Drug Administration, Human Services Department, Food · Oct 5, 2026, 11:00 PM CDT

The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early- phase clinical trials of ibogaine drug products and is opening a public docket to receive comments. The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adult

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Drug Administration →Human Services Department, Food →

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation

INSUFFICIENT CONTEXT

Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

FramingThe statement frames the FDA’s activity as proactive and collaborative, emphasizing public participation.

Authority AppealThe passage leverages the FDA’s regulatory authority to underscore the importance of the public’s input.

Contextual EmphasisLinking the ibogaine effort to existing psychedelic‑drug guidance situates the initiative within a broader regulatory trend.

Context

AI analysis

Missing context

The excerpt does not provide information about the current regulatory status of ibogaine (e.g., whether it is approved for any indication), prior safety data, or the specific agencies or institutions conducting the funded trials. It also lacks details on how the public can submit comments, the timeline for the docket, and any potential conflicts of interest among stakeholders.

Important context

The FDA’s request for information is part of a broader effort to establish regulatory frameworks for psychedelic‑derived therapeutics. The mention of HHS funding indicates federal investment in researching ibogaine for OUD and PTSD, conditions for which existing treatments have limitations. The reference to existing FDA guidance on psychedelic drugs suggests that ibogaine will be evaluated within an emerging regulatory paradigm for these substances.

Opinion vs. reporting

AI analysis

The text is purely informational and does not contain opinion; it reports agency actions and plans without evaluative language.

Publisher

Federal Register

United States

Ownership: U.S. Government (National Archives)

Publisher profile

Author

Health

Contributor

Beat: Government regulation, public health, Medicare, advisory committees, refugee assistance, chemical safety

Author profile

Author

Drug Administration

Official publisher of regulatory notices and requests for nominations, renewals, and submissions to the Office of Management and Budget.

Beat: Government regulation and public health, specifically FDA advisory committees, information collection, and medical device classification.

Author profile

Author

Human Services Department, Food

Publisher of official notices and requests for nominations, renewals, and classifications pertaining to FDA advisory committees and related regulatory matters.

Beat: Government regulation and public health, with a focus on FDA advisory committees, information collection activities, and regulatory filings.

Author profile

Primary sources cited

The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early‑phase clinical trials of ibogaine drug products and is opening a public docket to receive comments.
The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adults with opioid use disorder (OUD) and adults with post‑traumatic stress disorder (PTSD).
FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations" by seeking comments, data, and information from the public on protocol elements relevant to ibogaine development.